Latest News about MRK
Recent news which mentions MRK
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
Could Summit Therapeutics Become the Next Merck?
October 04, 2024
From Motley Fool
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
October 03, 2024
From Benzinga
The Covid Era Tech Promises To Reinvent Cancer Treatment
October 01, 2024
From Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
September 29, 2024
From Motley Fool
Evaxion Biotech Partners With Merck To Expand Vaccine Development
September 26, 2024
From Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
From Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
September 25, 2024
From Benzinga
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
September 25, 2024
From Benzinga
Pfizer Advances On Its Cancer Journey
September 20, 2024
From Benzinga
Is It Too Late to Buy ServiceNow Stock?
September 20, 2024
From Motley Fool
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
From Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Tickers
MRK
From Benzinga
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
From Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
From Motley Fool
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
From Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
From Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Tickers
MRK
From Benzinga
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
From Benzinga
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
September 13, 2024
From Benzinga
Is Summit Therapeutics a Buy Now?
September 10, 2024
From Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
From Motley Fool
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.